CLINICAL TRIAL: PHASE II TRIAL OF IDB 1016 IN ADULT DIABETIC PATIENTS WITH NASH

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 与卵磷脂安慰剂相比，使用Siliphos治疗6周是否安全且耐受性良好？ 在患有脂肪性肝炎的成年糖尿病患者中，服用Siliphos治疗后，胰岛素抵抗和/或氧化应激的改善是否会改善血清转氨酶水平所评估的脂肪肝疾病的活动性？

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Will treatment with Siliphos for six weeks be safe and well tolerated in comparison to lecithin placebo? In diabetic adult patients with steatohepatitis, will improvement in insulin resistance and/or oxidative stress due to treatment with Siliphos result in inprovement in fatty liver disease activity as assessed by serum aminotransferese levels?